Nuvation Bio Acquires AnHeart Therapeutics

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

Novacyt Acquires Yourgene Health plc

September 8, 2023

Medical Devices

Novacyt, through its wholly-owned subsidiary Novacyt UK Holdings Limited, has completed the acquisition of Yourgene Health plc by way of a court-sanctioned scheme of arrangement. The deal brings together Novacyt's diagnostics capabilities with Yourgene's genomic technologies and services to create a larger, diversified international molecular diagnostics business headquartered in Manchester, UK.

BioNTech Acquires Biotheus

February 3, 2025

Biotechnology

BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.

Northwell Health Completes Merger with Nuvance Health

May 7, 2025

Healthcare Services

Northwell Health and Nuvance Health have officially joined to form an integrated regional nonprofit health system serving communities across New York and Connecticut. The combined system will increase coordinated care capacity, expand access across inpatient and ambulatory sites, and enable at least $1 billion in Northwell investment into Nuvance hospitals.

Northwest Biotherapeutics Acquires Advent BioServices Ltd.

October 26, 2025

Biotechnology

Northwest Biotherapeutics (NWBio) has completed the acquisition of Advent BioServices Ltd., making Advent a wholly owned subsidiary. The deal transfers Advent's fixed assets, intellectual property and cryostorage capabilities to NWBio to support scale-up and integration of manufacturing capacity for NWBio's DCVax immunotherapy programs.